Soleus Capital Management, L.P. - KINNATE BIOPHARMA INC ownership

KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 60 filers reported holding KINNATE BIOPHARMA INC in Q3 2023. The put-call ratio across all filers is 0.76 and the average weighting 0.4%.

Quarter-by-quarter ownership
Soleus Capital Management, L.P. ownership history of KINNATE BIOPHARMA INC
ValueSharesWeighting
Q1 2021$3,396,000109,0000.61%
Other shareholders
KINNATE BIOPHARMA INC shareholders Q3 2023
NameSharesValueWeighting ↓
Foresite Capital Management IV, LLC 9,671,643$60,447,76931.36%
Vida Ventures Advisors, LLC 2,207,772$13,798,57518.88%
Lynx1 Capital Management LP 2,214,250$13,839,06311.54%
Foresite Capital Management V, LLC 1,975,001$12,343,7569.12%
Nextech Invest Ltd. 2,329,480$14,559,2506.08%
Ally Bridge Group (NY) LLC 109,393$683,7060.90%
Orbimed Advisors 5,143,629$32,147,6810.63%
RA Capital Management 4,264,144$26,650,9000.60%
Novo Holdings A/S 815,707$5,098,1690.34%
HARVARD MANAGEMENT CO INC 498,001$3,112,5060.33%
View complete list of KINNATE BIOPHARMA INC shareholders